These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 13161716)

  • 1. [Specific directed organic chemotherapy of carcinoma of the prostate].
    WILLMANNS H
    Dia Med; 1954 Apr; 26(24):564-8. PubMed ID: 13161716
    [No Abstract]   [Full Text] [Related]  

  • 2. [Focal organ specific chemotherapy in prostate cancer].
    WILMANNS H
    J Egypt Med Assoc; 1955; 38(1):14-8. PubMed ID: 14367635
    [No Abstract]   [Full Text] [Related]  

  • 3. [Directed, organ specific chemotherapy in prostate carcinoma].
    WILMANNS H
    Medizinische; 1954 Jan; 1():17-23. PubMed ID: 13144167
    [No Abstract]   [Full Text] [Related]  

  • 4. [Target chemotherapy of metastatic cancer of the prostate].
    RAABE S
    Krebsarzt; 1953 Dec; 8(11-12):321-3. PubMed ID: 13131792
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of Skp2 and P27kip1 protein expression and clinicopathological features of prostate cancer].
    Zheng XY; Ding W; Xie LP; Chen ZD
    Ai Zheng; 2004 Feb; 23(2):215-8. PubMed ID: 14960249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
    Wang W; Epstein JI
    Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary squamous cell carcinoma of the prostate: a case report].
    Inaba M; Boku H; Tanaka S; Fujito A
    Hinyokika Kiyo; 2007 Jan; 53(1):39-41. PubMed ID: 17310767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
    Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
    Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J; Hellman S
    Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
    Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
    Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer chemotherapy in the era of targeted therapy.
    Michael A; Syrigos K; Pandha H
    Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options in lymph node-positive prostate cancer.
    Swanson GP; Thompson IM; Basler J
    Cancer; 2006 Jun; 106(12):2531-9. PubMed ID: 16700035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylstilboestrol diphosphate, honvan (ST 52-asta), in intravenous tumour-specific chemotherapy of metastatic carcinoma of the prostate.
    HANSEN CC
    Acta Chir Scand; 1958 Apr; 114(5):398-413. PubMed ID: 13532319
    [No Abstract]   [Full Text] [Related]  

  • 19. Dilemmas in the treatment of urothelial cancers of the prostate.
    Walsh DL; Chang SS
    Urol Oncol; 2009; 27(4):352-7. PubMed ID: 18439852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
    Liedberg F; Chebil G; Månsson W
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):383-90. PubMed ID: 17338657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.